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Purpose. To evaluate functional and anatomic eﬀects of intravitreal bevacizumab in patients with neovascular AMD and initial low
visual acuity. Methods. Retrospective case series of 38 eyes with neovascular AMD and initial visual acuity of 20/200 or less, treated
with intravitreal bevacizumab injection. Results. Mean followup was 14.1 months ± 7.1 (range: 5 to 24 months). Mean logMAR
vision at baseline was 1.38 logMAR ± 0.33, at 6 months was 1.14 logMAR ± 0.37 (P = 0.001) and at 12 months was 1.22 logMar
± 0.33 (P = 0.004). Mean baseline central retinal thickness was 431µm ± 159.7 at 6 months was 293.43µm ± 122.79 (P = 10
−4)
and at 12 months was 293.1µm ± 130 (P = 0.004). Visual acuity improved in both patients with or without prior PDT treatment.
Conclusions. Intravitreal bevacizumab injection may increase the chance of visual acuity gain in neovascular AMD even in cases
with initial low visual acuity.
1.Introduction
Since the vascular endothelial growth factor (VEGF) has
been implicated as a major angiogenic stimulus responsible
for the formation of choroidal neovascularization (CNV) in
age-related macular degeneration (AMD) drugs inhibiting
the bioactivity of VEGF representing a new paradigm in the
treatment of neovascular AMD [1]; MARINA (Minimally
Classic/Occult Trial of the Anti-VEGF Antibody Ranibi-
zumabintheTreatmentofNeovascularAge-RelatedMacular
Degeneration) [2] and ANCHOR (Anti-VEGF Antibody for
the Treatment of Predominantly Classic Choroidal Neo-
vascularization in Age-Related Macular Degeneration) [3]
studies, both multicenter, randomized, double-masked tri-
als, established the eﬃcacy of ranibizumab (Lucentis) in
improving visual acuity in patients with both classic and
occult CNV. Both studies excluded individuals with very low
visual acuity (range, 20/40–20/320 in the MARINA study
and 20/80–20/120 in the ANCHOR study) and patients
previously treated with photodynamic therapy. However,
subgroup analysis of the MARINA trial noted that the
improvement in patients with initial visual acuity of 20/160
or less is lower than patients with better initial visual acuity
[4]. Therefore, there are limited data concerning the eﬀect
of anti-VEGF drugs in patient with neovascular AMD and
initial low visual acuity. Bevacizumab (Avastin; Genentech,
San Francisco, Calif, USA) is a full-length antibody against
all VEGF-A isoforms which is approved for use in metastatic
colon cancer and lately used for the treatment of AMD.
The purpose of the present study was to evaluate the
functional and the anatomic eﬀects of intravitreal beva-
cizumab in patients with wet AMD and initial low best
corrected visual acuity (BCVA).
2.MaterialsandMethods
We conducted a retrospective consecutive case series of 38
patients (38 eyes) with neovascular AMD and initial low
visual acuity in a referral centre for AMD patients in Tunisia
from June 2006 to December 2009.
An ophthalmic examination was performed, including
measurement of best-corrected visual acuity (BCVA) using
the ETDRS visual acuity protocol, slit-lamp biomicroscopy,
intraocular pressure (IOP) measurement and contact lens
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Figure 1: Evolution of change in logMar visual acuity over 14
months after intravitreal injection of bevacizumab showing statis-
tically signiﬁcant improvement.
ﬂuorescein angiography (FA; Imagenet; Topcon Corpora-
tion, Tokyo, Japan), indocyanine green angiography (ICGA),
and optical coherence tomography (OCT) scanning (OTI,
Toronto, Canada). The same experienced ophthalmologist
performed all FA, and OCT evaluations. The data recorded
included complains as scotoma, blurred vision and meta-
morphopsia, BVCA, lesion type on FA and central retinal
thickness (CRT) on OCT.
TheBCVAandOCTwereperformedatbaselineforevery
6 weeks. FA and ICGA were performed at baseline and every
3 months afterwards.
The following inclusion criteria were applied: (1) exuda-
tive AMD, (2) initial visual acuity of 20/200 or less, and (3)
with or without prior treatment of CNV as photodynamic
therapy or laser photocoagulation. The Exclusion criteria
were (1) subretinal ﬁbrosis involving central fovea and (2)
presence of other ocular pathology reducing vision.
Patients with BCVA better than 20/200 before treatment,
uncontrolled systemic arterial hypertension (blood pressure
>180/110mmHg), history of thromboembolic event, renal
disease, and recent surgery were excluded.
All patients were treated at baseline with intravitreal
bevacizumab (1.25mg/0.05mL). A standard protocol for
intravitreal injections was followed, including the operative
room, the use of topical 5% povidone-iodine, eyelid specu-
lum, and postoperative topical antibiotic drops. They were
asked to return the following day for assessment of IOP and
signs of intraocular inﬂammation or infection. Whenever
IOP exceeded 24mmHg, patients were given topical medi-
cation to reduce the pressure.
Indications for retreatment by IVB were deﬁned as per-
sistent subretinal and/or intraretinal ﬂuid on OCT for every
6 weeks. No repeat treatment was performed if cessation of
Table 1: Baseline features of patients with age-related macular
degeneration and initial low visual acuity.
Mean age + SD 73 + 6.24
Mean logMar VA 1.38
Mean greatest linear dimension (µ) 1748,02
Mean central retinal thickness (µm) 431 + 159.7
(range, 211–965)
No prior PDT 73.6%
Angiographic characteristic
Predominantly classic or classic 22 (28.9%)
Predominantly occult or occult 54 (71.05%)
CNV associated to Subretinal hemorrhage 4 (5.2%)
CNV associated to pigment epithelial
detachment 8 (10.5%)
LogMAR: logarithm of the minimum angle of resolution; VA: visual acuity;
OCT: optical coherence tomography; CNV: choroidal neovascularisation
dye leakage from the CNV was revealed in FA, as well as total
resolution of the subretinal ﬂuid on OCT.
For statistical analysis, ETDRS acuities were transformed
to log-MAR units (logarithm of the minimum angle of
resolution). Person correlation test, paired Wilcoxon test
and chi-square test were performed using SPSS 14.0 for
Windows. The paired Student’s t-test was used to statistically
evaluate changes in logMAR visual acuity and central retinal
thickness at diﬀerent time points. In all analyses, a P value
<0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. Baseline Characteristics. In the current study, 38 eyes of
38 patients were enrolled. The mean age of the patients (23
menand14women)was73years ±6.24(range62–82years).
The mean followup was 14.1 months ± 7.1 (range 5–24
months).
Ten patients (26.3%) had a history of photodynamic
therapy (PDT). CNV was minimally classic in 11 eyes
(28.9%), occult in 16 eyes (42.1%), predominantly classic
in 1 eye (2.6%), and classic in 10 eyes (26%). A pigment
epithelial detachment was present in 4 eyes (10.5%), a large
submacular haemorrhage was present in 2 eyes (5.2%), and
a disciform scars was present in 5 eyes (13.1%) (Table 1).
3.2. Visual Outcomes. The mean visual acuity (VA) at base-
line was 20/400 (logMAR 1–2, mean logMAR 1.38 ± 0.33)
(range hand movements to 20/200). VA was less than 20/200
in 30 patients (78.9%) and equal to 20/200 in 8 patients
(21%). Mean BCVA improved to 20/250 (1.17 logMAR),
and this diﬀerence was statistically signiﬁcant (P<0.001)
(Figure 1). At ﬁnal examination, 11 eyes (28.9%) showed
stable vision and only 3 eyes (8%) experienced visual acuity
worsening. Visual acuity improved in 24 eyes (63.2%) by 3
lines or more in 18 eyes (47.3%) with a mean gain of 2.32
lines. Metamorphopsia, blurred vision, and scotoma were
consistently reduced inducing the improvement of quality of
vision in all cases.Journal of Ophthalmology 3
Table 2: Visual acuity (VA) and central retinal thickness (CRT) outcome in patients previously treated with PDT compared with patients
without prior PDT.
Patients with prior PDT (n = 10) P Patients without prior PDT (n = 28) P
VA(LogMAR)
(i) At baseline 1.3 ± 0.24 1.4 ± 0.36
(ii) At ﬁnal examination 1.16 ± 0.15 0.043 1.18 ± 0.38 0.001
(iii) At 12 months 1.08 ± 0.2 0.039 1.28 ± 0.37 0.03
CRT (µm)
(i) At baseline 472.33 ± 61.23 427.11 ± 167.52
(ii) At ﬁnal examination 323.4 ± 159.6 0.1 301 ± 131.08 10−4
(iii) At 12 months 312.75 ± 184.9 0.18 313.31 ± 138.9 0.01
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Figure 2: Evolution of change in retinal thickness over 14 months
after intravitreal injection of bevacizumab showing statistically
signiﬁcant improvement.
Analysis of visual acuity in patients previously treated
with PDT (n = 10) and patients without prior PDT (n =
28) show that both groups beneﬁted from bevacizumab
treatment (Table 2). Visual acuity improved, respectively,
from 1.3 logMAR ± 0.24 to 1.16 logMAR ± 0.15 with a
statistically limit signiﬁcant diﬀerence (P = 0.043; paired
Wilcoxon test) in patients previously treated with PDT and
from1.4logMAR ±0.36to1.18logMAR ±0.38withstatisti-
cally signiﬁcant diﬀerence (P = 0.001; paired Wilcoxon test)
in non-PDT patients. Moreover the visual acuity improved
by 3 lines or more in 15 eyes (53.57%) in patients without
prior PDT compared with only 3 eyes (30%) in patients with
prior PDT.
3.3. Visual Acuity Analysis. At one month, mean BCVA
improved to 1.12 logMAR ± 0.37 (P = 10
−4, n = 37, paired
Student’s test). At 3 months, mean BCVA remained stable to
1.11 logMAR ± 0.36 (P = 10−4, paired Student’s test). At
the 6 month follow-up examination, mean BCVA was 1.14
logMAR ± 0.37 (P = 0.001, paired Student’s test), mean
gain was 2.15 lines ± 3.45. At the 9-month time point, mean
BCVA was 1.19 logMAR ± 0.36 (P = 0.003, paired Wilcoxon
t e s t ) ,m e a ng a i nw a s2l i n e s± 3.41. At 12 months, the mean
BCVAdecreasedslightlyto1.22logMar ±0.33butcompared
to baseline diﬀerence was also statistically signiﬁcant (P =
0.004, paired Wilcoxon test). Mean gain was 1.7 lines ± 3.07.
VA improved at least by three lines in 48%, was stable in
47.3%, and deteriorates in one patient. If we consider at
12 months only eyes without prior PDT treatment, visual
acuity was 1.28 logMAR ± 0.37 with a statistically signiﬁcant
diﬀerence (P = 0.033).
3.4.StatusofExudativeChanges(Figure 2). Average CRT was
431microns ± 159.7 (range 211–965) at baseline. The CRT
decreased statistically to 304.61µm ± 133.36 (range 123–
620µm) (P<0.001) (Figure 2).
The CRT decreased to 334.67µm ± 137.14 at one month,
to 318.67µm ± 124.12 at three months, to 293.43µm ±
122.79 at six months, and to 294.23µm ± 123.8 at nine
months (P = 10
−4, paired Wilcoxon test). At 12 months, the
Meancentralretinalthicknessremainedstableto293.1µm ±
130 (P = 0.004, paired Wilcoxon test).
CRT decreased, respectively, from 472.33µm ± 61.23 to
323.4µm ± 159.6 (P = 0.1; paired Wilcoxon test) in patients
previously treated with PDT (n = 10) and from 427.11µm ±
167.52 to 301µm ± 131.08 with a statistically signiﬁcant dif-
ference (P = 10
−4; paired Wilcoxon test) in patients without
prior PDT (n = 28). In this group, at 12 months mean
CRT was 313.31µm ± 138.9 and the diﬀerence was main-
tained statistically signiﬁcant (P = 0.01; paired Wilcoxon
test) (Table 2).
3.5.Retreatment. Patientsreceivedameanof2.86±0.77IVB
(range 2–5 injections). Twenty-one (55.2%) eyes received
three injections, 12 eyes (31.5%) received less than three
injections, and only ﬁve eyes (13.1%) received more than
three injections.
3.6.AdverseEﬀects. Atotalof109injectionswereperformed.
One case of retinal detachment had occurred. No other
ocular or systemic complications appeared during followup.4 Journal of Ophthalmology
4. Discussion
Early treatment of wet AMD may limit the CNV-induced
damage to the photoreceptors or the retinal pigment epithe-
lium, leading to a better visual acuity outcome. Unfor-
tunately, many patients are not diagnosed early nor have
chronic disease after receiving other treatment modalities
with low visual acuity [4, 5].
Our ﬁndings revealed in patients with low visual acu-
ity a statistically signiﬁcant improvement in visual acuity
associated with reduced foveal thickness on OCT after beva-
cizumab treatment. These ﬁndings compare well with other
series in the literature [5, 6] .E h r l i c he ta l .[ 5] and Galbinur
et al. report similar results, respectively, at 27 weeks and
3.9 months mean followup; here, we demonstrate that visual
improvement can last 6 and even 12 months after treatment.
In all included patients, VA was measured with the
ETDRS chart which is more accurate, in the lower VA range.
As patients do not have good ﬁxation, there was a learning
curveformeasurementsofvisualacuityand,moreover,OCT
has been more diﬃcult and longer to implement. So, several
scans were often needed to measure the central retinal thick-
ness and localize the fovea.
In our report, at 12 months, visual improvement
occurred in 48% of eyes (13/27) at least by three lines with
mean gain of 1.7 lines ± 3.07; stabilisation occurred in 48%
(13/27). The learning curve may aﬀect the improvement of
visual acuity after the treatment.
Overall, improvement in quality of vision, especially the
decrease of metamorphopsia, made the patient’s daily life
easier.Only one patient showed deterioration of her VA from
1.13 logMAR to 1.1 logMAR. There was a greater improve-
ment of VA in patients with no atrophic or ﬁbrotic changes,
who were not treated previously with PDT and in patients
with smaller size lesions.
Our study includes only ten patients with previous PDT
treatment. It is noteworthy that patients who were not
treatedpreviouslywithPDTbeneﬁtedmorefromintravitreal
bevacizumab compared with those who underwent prior
PDT due to possible damage caused by multiple PDT ses-
sions [5, 7]. We found a statistically signiﬁcant diﬀerence in
response between patients who had received PDT treatment
and those who had not and this is in accordance with the
report of Ehrlich et al. [5].
Visual improvement by three lines or more was found
in 48% of our patients and in 53.5% if we consider only
patients not treated with prior PDT; this ﬁnding is similar
to that of Galbinur et al. [6] who reported an improvement
of 43%, however, in the report of Ehrlich et al. [5], the
same improvement is limited to only 25%. The fact that the
majority of patients (66%) had previously received photo-
dynamic therapy while none of the patients of those treated
by Galbinur et al. [6] and only 26.3% of our patients had
previous photodynamic therapy.
In our study, the mean central retinal thickness was
signiﬁcantly reduced from 404µm to 291.50µm( P<0.001).
Signiﬁcant decrease in central retinal thickness was reported
b yE h r l i c he ta l .[ 5] measuring at baseline 324 ± 121µmt o
264 ± 65µm at ﬁnal examination (P = 0.02). We assumed
thatadecreaseintheleakageandabsorptionofthesubretinal
and intraretinal ﬂuid would improve the function of the
remaining viable photoreceptors.
In accordance with previous studies, signiﬁcant decrease
in central retinal thickness was seen from the ﬁrst to the
third month, where mean macular thickness decreased from
431µm ± 159.7 to 334.67µm ± 137.14 at one month and to
318.67µm ± 124.12 at 3 months showing rapid eﬀect during
treatment.From6to12months,macularthicknessremained
stable.
Our data indicate that intravitreal bevacizumab injection
results in a signiﬁcant improvement in functional and ana-
tomic outcomes from the ﬁrst month after injection, main-
tained at 12 months after treatment. In the absence of sub-
foveal ﬁbrosis, intravitreal bevacizumab injection is beneﬁ-
cial in patients with neovascular AMD and severe vision loss.
Treatment decisions should not be based on the visual acuity
but on the characteristics of the lesion.
The strength of our study is a long follow-up period,
use of standardized ETDRS protocol visual acuity data and
acquisition of OCT data at each follow-up visit and by
the same investigator. Limitation of this study includes its
retrospective design with lack of a control group.
Our results suggest that intravitreal bevacizumab is well
tolerated and may increase the chance of visual acuity gain in
neovascular age-related macular degeneration even in cases
with initial low vision. So, this study supports the ﬁndings
of previously published series regarding the short-term
improvement in visual acuity and central retinal thickness
but suggests 6- and 12-month improvement. Given the high
percentage of patients who present with advanced AMD,
larger controlled trials are warranted.
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